Immuno-oncology's evolution: Implications for pharma market researchers
In association with PMGroup
Immuno-oncology therapies that harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. Until recently only a few products had reached the market for a limited number of indications.
However, over the past 12 months several new products have been approved for a wider range of tumour types and with numerous other products in the pipeline, competition looks set to hot up.
Webcast: Understanding Patient Willingness to Pay
What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets? Download this complimentary webcast in which our emerging markets experts Paul Reed and Helen Mace explore the key features of self-pay markets and outline the critical success factors for determining how pharmaceutical, consumer health products and medical devices should be priced.
Webinar: Ensuring an Actionable Segmentation
A segmentation study comes with high visibility and high stakes across your marketing and sales organisations. Ensuring that a segmentation is actionable is a consistent issue, particularly when stakeholders with multiple interests are involved. Download our latest webcast in which our quantitative experts Tom Nolte and Dr Marianne Jaeger will utilise knowledge and experience garnered from more than 25 years of conducting global segmentations, to explore some of the key segmentation challenges and show you how to ensure adoption and use across your business.
What next for biosimilars?
Biosimilar medicines appear to present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems. However, these drugs aren’t cheap or easy to manufacture and come with considerable marketing challenges.
Join market research consultants Laurent Chanroux and Richard Head for this complimentary webinar in which they will explore and compare biosimilars in RA and diabetes.
Understanding the Chronic Disease Patient Journey in Emerging Markets
With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffer from chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West.
The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to fully exploit these potential new markets.